Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DRMA
Upturn stock ratingUpturn stock rating

Dermata Therapeutics Inc (DRMA)

Upturn stock ratingUpturn stock rating
$0.58
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $3

1 Year Target Price $3

Analysts Price Target For last 52 week
$3Target price
Low$0.57
Current$0.58
high$3.79

Analysis of Past Performance

Type Stock
Historic Profit -31.11%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.85M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 1
Beta 0.57
52 Weeks Range 0.57 - 3.79
Updated Date 06/30/2025
52 Weeks Range 0.57 - 3.79
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.42

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -95.9%
Return on Equity (TTM) -206.26%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -5864334
Price to Sales(TTM) -
Enterprise Value -5864334
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.58
Shares Outstanding 6378120
Shares Floating 4154323
Shares Outstanding 6378120
Shares Floating 4154323
Percent Insiders 18.16
Percent Institutions 8.13

Analyst Ratings

Rating 1
Target Price 3
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Dermata Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing innovative, differentiated, and patent-protected therapeutics for the treatment of common skin diseases. Founded to address unmet needs in dermatology, the company has advanced multiple product candidates through clinical development.

business area logo Core Business Areas

  • Medical Dermatology: Focuses on developing and commercializing therapies for common skin conditions like acne, rosacea, and seborrheic dermatitis.

leadership logo Leadership and Structure

Dermata's leadership team consists of experienced executives in dermatology and pharmaceutical development. The organizational structure is typical of a clinical-stage biotech company, with teams dedicated to research, clinical development, regulatory affairs, and commercialization planning.

Top Products and Market Share

overview logo Key Offerings

  • DRM01 (Seborrheic Dermatitis): DRM01 is a novel, investigational therapy for seborrheic dermatitis, currently in clinical development. No market share data is available as the product is not yet approved. Competitors include topical steroids, antifungals (e.g., ketoconazole), and calcineurin inhibitors.
  • DRM02 (Acne): DRM02 is an investigational topical treatment for acne. No market share data is available as the product is not yet approved. Competitors include benzoyl peroxide, retinoids, and antibiotics.

Market Dynamics

industry overview logo Industry Overview

The medical dermatology market is characterized by a growing demand for effective treatments for common skin conditions, driven by increasing awareness, an aging population, and a desire for improved aesthetic outcomes. The market is competitive, with both established pharmaceutical companies and emerging biotech firms developing innovative therapies.

Positioning

Dermata is positioned as an innovator in medical dermatology, focused on developing differentiated products that address unmet needs. Their competitive advantage lies in their proprietary technologies and targeted approach to drug development.

Total Addressable Market (TAM)

The global dermatology market is estimated to be in the billions of dollars. Dermata is positioned to capture a portion of this TAM by targeting specific indications with innovative therapies.

Upturn SWOT Analysis

Strengths

  • Proprietary technology platform
  • Experienced management team
  • Promising clinical trial results
  • Strong intellectual property protection

Weaknesses

  • Reliance on successful clinical trials
  • Limited financial resources as a clinical-stage company
  • Dependence on regulatory approvals
  • Lack of established commercial infrastructure

Opportunities

  • Expansion into new dermatological indications
  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial outcomes leading to regulatory approval
  • Growing demand for innovative dermatology treatments

Threats

  • Competition from established players
  • Failure of clinical trials
  • Regulatory setbacks
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • LEO
  • VRX
  • BMY
  • LLY

Competitive Landscape

Dermata faces significant competition from established pharmaceutical companies with broader portfolios and greater resources. Dermata's advantage lies in its focused approach and potentially differentiated products.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by advancements in clinical development and pipeline expansion.

Future Projections: Future growth depends on the successful development and commercialization of its product candidates. Analyst estimates will be based on clinical trial data and market potential.

Recent Initiatives: Recent initiatives include advancing DRM01 and DRM02 through clinical trials and exploring potential partnerships.

Summary

Dermata Therapeutics is a clinical-stage company with promising dermatology assets, facing the typical risks of pharmaceutical development. Its success hinges on positive clinical trial results and subsequent regulatory approvals. While its focused approach is an advantage, limited resources and competition pose significant challenges. The company needs to continue executing its clinical strategy efficiently and seek strategic partnerships to enhance its commercialization potential.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company press releases
  • SEC filings
  • Industry reports
  • Analyst reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be considered a recommendation to buy or sell any securities. Market share data are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Dermata Therapeutics Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2021-08-13
Founder, President, CEO & Chairman Mr. Gerald T. Proehl
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.